13 results
Primary Objective: The objective of this project is to explore the role of adenosine receptor stimulation in the protective effect of rosuvastatin against ischemia-reperfusion injury after ischemic exercise of the forearm.Secondary Objective(s):…
To study the possible relation between systemic inflammation and oxidative stress and muscle breakdown using pharmacological interventions.
We hypothesise that aspirin 100mg at bedtime decreases tension by nocturnally lessening increase of the renin-angiotensin-aldosterone system, enhancing NO bioavailability, lessening autonomous nervous system activity and inhibiting COX-1 dependent…
The results of this study will give better insights in the role of ADMA in the development of systemic endothelial dysfunction.
Objective of the study is to investigate the effects of aspirin on the platelet function of healthy volunteers and of patients with ischemic stroke. In another part of the study, we will investigate whether or not the effects of aspirin on the…
To study the influence of caffeine on post occlusive reactive hyperaemia before and after 7 days treatment with rosuvastatin.
To study the protective effect of pretreatment (both 3 day and 7 day) with rosuvastatin and atorvastatin on flow mediated dilation after 15 minutes ischemia and 15 minutes reperfusion.
Primary Objective: to investigate the effect of rosuvastatin 20 mg qd on subsequent immune activation markers in treatment-naïve HIV-patients: circulating LPS (LAL assay), TLR mRNA expression in whole blood, circulating IL-6, D-dimer, hsCRP, CD38…
The aim of our project is to study whether treatment with aspirin at bedtime compared with intake at morning has additional benefits in patients using aspirin to prevent recurrent cardiovascular events. 1. Our primary objective is to study the…
The results of this study will give better insights in the role of ADMA in the development of systemicendothelial dysfunction and the relation with mild renal insufficiency.
The primary objective of this study is to determine whether LY2484595, administered incombination with atorvastatin for 12 weeks to patients with hypercholesterolemia or low HDL-C, will significantly increase mean HDL-C and decrease mean LDL-C from…
To perform a pilot study to determine the feasibility of conducting a two-arm phase I trial and to determine the recommended dose level for phase II (RP2D) study and assess the safety of the combination olaparib and melphalan in patients with…
Primary ObjectivesIn patients with primary hypercholesterolemia and high cardiovascular risk with LDL-C >=100 mg/dL (2.59 mmol/L) and <=160 mg/dL (4.14 mmol/L), to evaluate:1)at the end of Phase I, the additional LDL-C percentage…